• Login
    Search 
    •   Home
    • Articles and other publications by RIVM employees
    • Search
    •   Home
    • Articles and other publications by RIVM employees
    • Search
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of WARPCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsPublisherDepartmentThis CommunityTitleAuthorsIssue DateSubmit DateSubjectsPublisherDepartment

    My Account

    LoginRegister

    Filter by Category

    Subjectsepidemiology (3)Screening (3)Antimicrobial resistance (2)Children (2)HPV (2)View MoreJournalInt J Cancer 2018; advance online publication (ahead of print) (6)Clin Infect Dis 2018; advance online publication (ahead of print) (4)Infectieziekten Bulletin 2018; 29(3) (4)Toxicol in Vitro 2018; advance online publication (ahead of print) (4)Epidemiol Infect 2018; advance online publication (ahead of print) (3)View MoreAuthorsTrichopoulou, Antonia (59)Tumino, Rosario (56)Tjønneland, Anne (55)Boeing, Heiner (54)Overvad, Kim (54)View MoreYear (Issue Date)2010 - 2019 (1234)2003 - 2009 (232)TypesArticle (1416)Book chapter (4)Working Paper (2)article (1)Thesis (1)

    Statistics

    Display statistics
     

    Search

    Show Advanced FiltersHide Advanced Filters

    Filters

    Now showing items 1-10 of 1466

    • List view
    • Grid view
    • Sort Options:
    • Relevance
    • Title Asc
    • Title Desc
    • Issue Date Asc
    • Issue Date Desc
    • Results Per Page:
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100

    • 1466CSV
    • 1466RefMan
    • 1466EndNote
    • 1466BibTex
    • Selective Export
    • Select All
    • Help
    Thumbnail

    The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reversetranscription polymerase chain reaction.

    Mohran, K A; Farag, E A B; Reusken, C B E; Raj, V S; Lamers, M M; Pas, S D; Voermans, J; Smits, S L; Alhajri, M M; Alhajri, F; Al-Romaihi, H E; Ghobashy, H; El-Maghraby, M M; Al Dhahiry, S H S; Al-Mawlawi, N; El-Sayed, A M; Al-Thani, M; Al-Marri, S A; Haagmans, B L; Koopmans, M P G (2016-12)
    The newly identified Middle East respiratory syndrome coronavirus (MERS-CoV), which causes severe respiratory disease, particularly in people with comorbidities, requires further investigation. Studies in Qatar and elsewhere have provided evidence that dromedary camels are a reservoir for the virus, but the exact modes of transmission of MERS-CoV to humans remain unclear. In February 2014, an assessment was made of the suitability and sensitivity of different types of sample for the detection of MERSCoV by real-time reverse-transcription polymerase chain reaction (RT-PCR) for three gene targets: UpE (upstream of the E gene), the N (nucleocapsid) gene and open reading frame (ORF) 1a. Fifty-three animals presented for slaughter were sampled. A high percentage of the sampled camels (79% [95% confidence interval 66.9-91.5%, standard error 0.0625]; 42 out of 53) were shown to be shedding MERS-CoV at the time of slaughter, yet all the animals were apparently healthy. Among the virus-positive animals, nasal swabs were most often positive (97.6%). Oral swabs were the second most frequently positive (35.7%), followed by rectal swabs (28.5%). In addition, the highest viral load, expressed as a cycle threshold (Ct) value of 11.27, was obtained from a nasal swab. These findings lead to the conclusion that nasal swabs are the candidate sample of choice for detecting MERS-CoV using RT-PCR technology in apparently healthy camels.
    Thumbnail

    'Happy the man, who, studying nature's laws, Thro' known effects can trace the secret cause.' Do we have enough pieces to solve the pyrazinamide puzzle?

    Anthony, R M; den Hertog, A L; van Soolingen, D (2018-03-08)
    A low pH was assumed to be required for the activity of pyrazinoic acid (the active form of pyrazinamide) against Mycobacterium tuberculosis, but recently activity has been demonstrated at neutral pH. Renewed interest in pyrazinamide has led to an increasing number of potential targets and the suspicion that pyrazinamide is a 'dirty drug'. However, it is our opinion that the recent demonstration that pyrazinoic acid is active against PanD provides an alternative explanation for the secret of pyrazinamide's unusual activity. In this article we propose that PanD is the primary target of pyrazinoic acid but expression of pyrazinoic acid susceptibility requires an intact stress response. As the mycobacterial stress response requires the interaction of a number of genes, disruption of any could result in an inability to enter the susceptible phenotype. We believe this model can explain most of the recent observations of the seemingly diverse spectrum of activity of pyrazinamide.
    Thumbnail

    Response to letters to the editor regarding our paper "Early introduction of complementary foods and childhood overweight in breastfed and formula-fed infants in the Netherlands: the PIAMA birth cohort study".

    Pluymen, Linda P M; Wijga, Alet H; Gehring, Ulrike; Koppelman, Gerard H; Smit, Henriëtte A; van Rossem, Lenie (2018-05-16)
    Thumbnail

    New and emerging risks of chemical carcinogens: detection and prevention.

    Palmen, Nicole G M; Lenderink, Annet F; Godderis, Lode (2018-03-27)
    Thumbnail

    Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity.

    Bal-Price, Anna; Hogberg, Helena T; Crofton, Kevin M; Daneshian, Mardas; FitzGerald, Rex E; Fritsche, Ellen; Heinonen, Tuula; Hougaard Bennekou, Susanne; Klima, Stefanie; Piersma, Aldert H; Sachana, Magdalini; Shafer, Timothy J; Terron, Andrea; Monnet-Tschudi, Florianne; Viviani, Barbara; Waldmann, Tanja; Westerink, Remco H S; Wilks, Martin F; Witters, Hilda; Zurich, Marie-Gabrielle; Leist, Marcel (2018-02-23)
    Multiple non-animal-based test methods have never been formally validated. In order to use such new approach methods (NAMs) in a regulatory context, criteria to define their readiness are necessary. The field of developmental neurotoxicity (DNT) testing is used to exemplify the application of readiness criteria. The costs and number of untested chemicals are overwhelming for in vivo DNT testing. Thus, there is a need for inexpensive, high-throughput NAMs, to obtain initial information on potential hazards, and to allow prioritization for further testing. A background on the regulatory and scientific status of DNT testing is provided showing different types of test readiness levels, depending on the intended use of data from NAMs. Readiness criteria, compiled during a stakeholder workshop, uniting scientists from academia, industry and regulatory authorities are presented. An important step beyond the listing of criteria, was the suggestion for a preliminary scoring scheme. On this basis a (semi)-quantitative analysis process was assembled on test readiness of 17 NAMs with respect to various uses (e.g. prioritization/screening, risk assessment). The scoring results suggest that several assays are currently at high readiness levels. Therefore, suggestions are made on how DNT NAMs may be assembled into an integrated approach to testing and assessment (IATA). In parallel, the testing state in these assays was compiled for more than 1000 compounds. Finally, a vision is presented on how further NAM development may be guided by knowledge of signaling pathways necessary for brain development, DNT pathophysiology, and relevant adverse outcome pathways (AOP).
    Thumbnail

    Hoeveel klinische geneesmiddelenstudies worden uiteindelijk gepubliceerd?

    van den Bogert, C A; Souverein, P C; Brekelmans, C T M; Janssen, S W J; Koëter, G H; Leufkens, H G M; Bouter, L M (2017)
    The objective of this study was to investigate the occurrence and determinants of non-publication of clinical drug trials in the Netherlands. All clinical drug trials reviewed by the 28 Institutional Review Boards (IRBs) in the Netherlands in 2007 were followed-up from approval to publication. Candidate determinants were the sponsor, phase, applicant, centers, therapeutic effect expected, type of trial, approval status of the drug(s), drug type, participant category, oncology or other disease area, prospective registration, and early termination. The main outcome was publication as peer reviewed article. The percentage of trials that were published, crude and adjusted odds ratio (OR), and 95% confidence interval (CI) were used to quantify the associations between determinants and publication. In 2007, 622 clinical drug trials were reviewed by IRBs in the Netherlands. By the end of follow-up, 19 of these were rejected by the IRB, another 19 never started inclusion, and 10 were still running. Of the 574 trials remaining in the analysis, 334 (58%) were published as peer-reviewed article. The multivariable logistic regression model identified the following determinants with a robust, statistically significant association with publication: phase 2 (60% published; adjusted OR 2.6, 95% CI 1.1-5.9), phase 3 (73% published; adjusted OR 4.1, 95% CI 1.7-10.0), and trials not belonging to phase 1-4 (60% published; adjusted OR 3.2, 95% CI 1.5 to 6.5) compared to phase 1 trials (35% published); trials with a company or investigator as applicant (63% published) compared to trials with a Contract Research Organization (CRO) as applicant (50% published; adjusted OR 1.7; 95% CI 1.1-2.8); and multicenter trials also conducted in other EU countries (68% published; adjusted OR 2.2, 95% CI 1.1-4.4) or also outside the European Union (72% published; adjusted OR 2.0, 95% CI 1.0-4.0) compared to single-center trials (45% published). Trials that were not prospectively registered (48% published) had a lower likelihood of publication compared to prospectively registered trials (75% published; adjusted OR 0.5, 95% CI 0.3-0.8), as well as trials that were terminated early (33% published) compared to trials that were completed as planned (64% published; adjusted OR 0.2, 95% CI 0.1-0.3). The non-publication rate of clinical trials seems to have improved compared to previous inception cohorts, but is still far from optimal, in particular among phase 1, single-center, not prospectively registered, and early terminated trials.
    Thumbnail

    Pilletje voor de partner bij chlamydia?

    Götz, Hannelore M; van Bergen, Jan E A M; Philips-Santman, Cezanne; van Benthem, Birgit H B (2018-05-18)
    Effective partner notification and partner treatment are essential to prevent reinfection with Chlamydia trachomatis. For this reason we investigated the possibilities for patient-initiated partner therapy (PIPT) in the Netherlands.
    Thumbnail

    A novel multiplex poliovirus binding inhibition assay applicable for large serosurveillance and vaccine studies, without the use of live poliovirus.

    Schepp, Rutger M; Berbers, Guy A M; Ferreira, José A; Reimerink, Johan H; van der Klis, Fiona R (2017)
    Large-scale serosurveillance or vaccine studies for poliovirus using the "gold standard" WHO neutralisation test (NT) are very laborious and time consuming. With the polio eradication at hand and with the removal of live attenuated Sabin strains from the oral poliovirus vaccine (OPV), starting with type 2 (as of April 2016), laboratories will need to conform to much more stringent laboratory biosafety regulations when handling live poliovirus strains. In this study, a poliovirus binding inhibition multiplex immunoassay (polio MIA) using inactivated poliovirus vaccine (IPV-Salk) was developed for simultaneous quantification of serum antibodies directed to all three poliovirus types. Our assay shows a good correlation with the NT and an excellent correlation with the ELISA-based binding inhibition assay (POBI). The assay is highly type-specific and reproducible. Additionally, serum sample throughput increases about fivefold relative to NT and POBI and the amount of serum needed is reduced by more than 90%. In conclusion, the polio MIA can be used as a safe and high throughput application, especially for large-scale surveillance and vaccine studies, reducing laboratory time and serum amounts needed.
    Thumbnail

    Corrigendum to "A modelling study to evaluate the costs and effects of lowering the starting age of population breast cancer screening" [Maturitas 109 (2018) 81-88].

    Koleva-Kolarova, Rositsa G; Daszczuk, Alicja M; de Jonge, Chris; Abu Hantash, Mohd Khalil; Zhan, Zhuozhao Z; Postema, Erik Jan; Feenstra, Talitha L; Pijnappel, Ruud M; Greuter, Marcel J W; de Bock, Geertruida H (2018-05-17)
    Thumbnail

    Environmental Surveillance of Zoonotic Francisella tularensis in the Netherlands

    Janse, Ingmar; van der Plaats, Rozemarijn Q. J.; de Roda Husman, Ana Maria; van Passel, Mark W. J. (2018-05-08)
    • 1
    • 2
    • 3
    • 4
    • . . .
    • 147
    DSpace software (copyright © 2002 - 2019)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.